Search Within

Solid Tumor Oncology Division

  1. "Department of Medicine"
Formats
  1. Journal Article (10774)
  2. Meeting Abstract (9390)
  3. Review (538)
  4. Book Section (408)
  5. Editorial (319)
  6. Guidelines (150)
  7. Correspondence (111)
  8. Conference Paper (105)
  9. Research Letter (59)
  10. Miscellaneous (52)
  11. Book Whole (27)
Groups
  1. Department of Medicine (21933)
  2. GSK Faculty (5859)
  3. Genitourinary Oncology Service (5574)
  4. Survivorship Research (5168)
  5. Gastrointestinal Oncology Service (4619)
  6. Breast Medicine Service (4090)

More Groups

People
  1. Robert Motzer (1238)
  2. Howard Scher (1127)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (868)
  6. Leonard Saltz (789)

More People

Years
  1. 2025 (347)
  2. 2024 (1369)
  3. 2023 (1374)
  4. 2022 (1573)
  5. 2021 (1514)
  6. 2020 (1533)

More Years

Publications
  1. Journal of Clinical Oncology (5209)
  2. Annals of Oncology (1289)
  3. Cancer Research (1010)
  4. Clinical Cancer Research (765)
  5. Journal of Thoracic Oncology (517)
  6. Gynecologic Oncology (437)

More Publications

Publishers
  1. American Society of Clinical Oncology (5483)
  2. Elsevier Inc. (2622)
  3. American Association for Cancer Research (2309)
  4. Oxford University Press (1800)
  5. Nature Publishing Group (1014)
  6. Springer (974)

More Publishers

Results (21933)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes with first-line ipilimumab and nivolumab for patients with metastatic renal cell carcinoma by number of doses
    Meeting Abstract

    Doshi, S. D.; Sanmiguel, A. L.; Knezevic, A.; Kotecha, R. R.; Shah, N. J.; Carlo, M.; Feldman, D. R.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and novel immunotherapy agents for advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Suárez, C.; Albiges, L.; Beckermann, K.; Hammers, H. J.; Stadler, W. M.; Miller, W. H. Jr; Rojas, C.; Peer, A.; Goh, J. C.; Park, S. H.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Precision diagnostics in prostate cancer treatment (PREDICT): A phase 2 multi-arm biomarker-based study (Alliance A032102)
    Meeting Abstract

    McKay, R. R.; Heller, G.; Zhao, S.; Wulff-Burchfield, E. M.; Shah, D.; Tan, A.; Galsky, M. D.; Rosenberg, J. E.; Beltran, H.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib + pembrolizumab (L+P) in the phase 3 CLEAR trial
    Meeting Abstract

    Grünwald, V.; Keizman, D.; Bedke, J.; Staehler, M. D.; Matveev, V. B.; George, S.; Hutson, T. E.; Vaishampayan, U. N.; Merchan, J. R.; Eto, M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Powles, T.; Van Der Heijden, M. S.; Loriot, Y.; Bedke, J.; Valderrama, B. P.; Iyer, G.; Kikuchi, E.; Hoffman-Censits, J.; Vulsteke, C.; Drakaki, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial
    Meeting Abstract

    Motzer, R. J.; Escudier, B.; Burotto, M.; Powles, T.; Apolo, A. B.; Bourlon, M. T.; Shah, A. Y.; Porta, C.; Suárez, C.; Barrios, C. H.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Albiges, L.; Suárez, C.; Powles, T.; Motzer, R. J.; Stadler, W. M.; Miller, W. H. Jr; Rojas, C.; Peer, A.; Goh, J. C.; Park, S. H.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313
    Meeting Abstract

    Albiges, L.; Motzer, R. J.; Trevino, S.; Kanesvaran, R.; Centkowski, P.; Reimers, M. A.; Sade, J. P.; Pouessel, D.; Biscaldi, E.; Esteban, E.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC)
    Meeting Abstract

    McGregor, B. A.; Choueiri, T. K.; Albiges, L.; Beckermann, K.; Barthelemy, P.; Iacovelli, R.; Emambux, S.; Molina-Cerrillo, J.; Garmezy, B.; Barata, P. C.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1
    Meeting Abstract

    Iyer, G.; Ebi, H.; Cook, N.; Gao, X.; Kitano, S.; Matsubara, N.; Reimers, M. A.; Siefker-Radtke, A. O.; Kim, M.; Galsky, M. D.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save